Hims & Hers Health is up 25% since the beginning of the year, but at $31.50 per share, it is still trading 54.2% below its 52-week high of $68.74 from February 2025.

Hims & Hers Health (NYSE: HIMS) stock jumped 2.2% through 10:45 a.m. ET Monday after Morgan Stanley analyst Craig Hettenbach delivered some good news for the mail-order drugs stock. Citing third ...

Bank of America raised its price target on Hims & Hers Health, but still thinks you should sell the stock. February saw a spike in weight loss sales at the drug compounder, but future sales of ...

Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

Although the telemedicine company displayed blistering growth and issued robust guidance, shares of Hims & Hers (NYSE: HIMS) plummeted following its fourth-quarter earnings report. The stock had ...

Telehealth company Hims & Hers (HIMS) saw a major boost in app downloads during February. According to a Top-rated analyst, Craig Hettenbach from Morgan Stanley (MS), third-party data revealed a ...

Both Hims and Keeps offer viable options for treating hair loss. Choosing between the two could come down to product choice, customer service, and personal preference. Share on Pinterest Find out ...